A continuaciónSiguiente guía
Monitoreo de empleados por IA y vigilancia del lugar de trabajo
sociedad
GUÍA de sociedad
AI in Prescription Drug Monitoring Programs
AI in prescription drug monitoring programs (PDMPs) refers to algorithms, such as Bamboo Health's NarxCare, that analyze a patient's history of controlled-substance prescriptions and produce risk scores that pharmacists and prescribers see when they check the state database.
En esta pagina4 minutos de lectura
Descripción general
It matters because these scores can influence whether a prescription is filled or a patient is treated. Critics argue the scores can penalize people with complex medical needs while offering little transparency or way to appeal.
Buceo profundo
Almost every US state runs a PDMP: a database where pharmacies report dispensed controlled substances. Clinicians and pharmacists check it before prescribing or dispensing. Many states and pharmacy systems add NarxCare, a platform from Bamboo Health (formerly Appriss Health), which displays analytics on top of the raw history. NarxCare shows separate Narx scores for narcotics, sedatives and stimulants. Each is a three-digit number from 000 to 999, and the last digit shows how many active prescriptions of that type the patient has. It also shows an Overdose Risk Score and visual summaries. The inputs are patterns in the records: how many prescribers and pharmacies are involved, total dose (often expressed in morphine milligram equivalents), overlapping prescriptions and how recent the fills are. For pharmacists the stakes are specific. Under federal rules, pharmacists share a 'corresponding responsibility' with the prescriber to make sure a controlled-substance prescription serves a legitimate medical purpose. A high score can prompt a call to the prescriber, a delay, a refusal to fill, or an offer of naloxone. Bamboo Health has said the scores are not meant to be the sole basis for clinical decisions. The CDC's 2022 opioid prescribing guideline also warns clinicians against dismissing patients based on PDMP information. There are several main criticisms. The model is proprietary, so patients and clinicians cannot see exactly how a score was calculated. People with cancer, chronic pain or multiple specialists naturally have more prescribers and pharmacies. Pet prescriptions filled under an owner's name can raise the owner's score. Legal scholars, including Jennifer Oliva, have argued these tools can discriminate against patients with disabilities or complex conditions. There is also no standard way for patients to see or dispute a score. A common misconception is that a high score means addiction or diversion. It reflects a pattern of prescriptions, not a diagnosis of the patient.
Impacto Estratégico
Riesgo y seguridad
Los daños catastróficos y cotidianos de la IA dependen de quién comprende los riesgos y quién puede actuar.
Decisiones más claras
La alfabetización pública y profesional determina si es políticamente posible una política de seguridad sólida.
Cortando el bombo
Las explicaciones claras reducen la captación por la exageración, las relaciones públicas de laboratorio y el vago teatro de ética.
The Future of AI in Prescription Drug Monitoring Programs
Pressure for transparency is growing. Pain-patient advocates, legal scholars and some clinicians want disclosure of the inputs, validation results broken down by patient group, and a way for patients to see and correct their records. Some states may add rules about how scores can be used in dispensing decisions, though the approach varies. Better separation of veterinary prescriptions and better record matching would remove known sources of error. How far these tools actually reduce overdoses while protecting access for legitimate patients is still an open question that needs independent evaluation.
Implementación en el mundo real
A pharmacist sees a high narcotic score for a patient filling an oxycodone prescription. He opens the full PDMP history and finds prescriptions from one oncologist and one surgeon after a documented cancer surgery, so he fills it and offers naloxone.
A patient's sedative score rises because of benzodiazepine prescriptions written for her dog, which were recorded under her name. Her pharmacist has to call the veterinarian to confirm the explanation.
A pharmacy chain's policy says a high score alone is not a reason to refuse. Pharmacists must look at specific warning signs, such as overlapping prescriptions from unrelated prescribers, and speak with the prescriber.
A pain clinic sees a patient whose record shows many pharmacies. The pharmacies turn out to reflect insurance changes and drug shortages, which shows how a factor the score counts can have an ordinary explanation.
Riesgos y barandillas
Tratar el riesgo existencial como ciencia ficción mientras que la capacidad se agrava.
Confundir la seguridad del producto superficial con la alineación en condiciones de alta autonomía.
Dejando a las audiencias que no hablan inglés ni a expertos solo con fuentes de baja calidad.
Hoja de ruta de implementación
Separe los riesgos de daños al producto, mal uso y pérdida de control/desalineación.
Pregunte qué evidencia cambiaría su opinión sobre los plazos y la gravedad.
Prefiera fuentes primarias y evaluaciones concretas a afirmaciones de marketing.
Identifique un camino de acción: carrera, política, financiamiento o habilidades, no solo concientización.
Sigue explorando
Free newsletter
Get the daily AI briefing
Three verified AI stories every weekday morning, written in plain English. Free forever, no ads.
One email each weekday. Unsubscribe in one click. We never sell or share your address.
Test yourself
Take the AI in Prescription Drug Monitoring Programs quiz
Instant feedback on every answer, and a shareable certificate with a verifiable ID once you pass a course.
Support free AI education. AI Understanding is a 501(c)(3) nonprofit — no ads, no paywall, ever. Make a donation
Preguntas frecuentes
What is AI in Prescription Drug Monitoring Programs?
AI in prescription drug monitoring programs (PDMPs) refers to algorithms, such as Bamboo Health's NarxCare, that analyze a patient's history of controlled-substance prescriptions and produce risk scores that pharmacists and prescribers see when they check the state database. It matters because these scores can influence whether a prescription is filled or a patient is treated. Critics argue the scores can penalize people with complex medical needs while offering little transparency or way to appeal.
En una puntuación de narcóticos de NarxCare de 452, ¿qué representa el último dígito 2?
El último dígito de cada puntuación Narx de tres dígitos muestra cuántas recetas activas de ese tipo tiene el paciente.
¿Por qué la prescripción de benzodiacepinas a un perro puede aumentar la puntuación de sedantes de su dueño?
Cuando las recetas para mascotas se registran bajo el nombre del propietario, parecen ser las del propio propietario y elevan la puntuación.
Según las normas federales, ¿qué "responsabilidad correspondiente" comparten los farmacéuticos con los prescriptores?
Los farmacéuticos comparten la responsabilidad de garantizar que las recetas de sustancias controladas sean legítimas, razón por la cual una puntuación puede afectar si surten una o no.
¿Contra qué advierte a los médicos la directriz sobre opioides de 2022 de los CDC, como se indica en la guía?
La guía advierte contra el despido de pacientes debido a los hallazgos del PDMP, lo que encaja con la opinión de que las puntuaciones no deberían decidir la atención por sí solas.
Un paciente con cáncer consulta a un oncólogo, un cirujano y un especialista en dolor. ¿Por qué su puntuación podría ser alta incluso con la atención adecuada?
Tener varios prescriptores y farmacias es un insumo para la puntuación. La atención compleja pero legítima produce el mismo patrón que el modelo considera riesgoso.
sigue aprendiendo
Guías relacionadas
Más guías seleccionadas para este tema.